Tasigna is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Nilotinib.
| Product ID | 0078-0526_404b85a1-6329-432c-a18f-a9588c009551 |
| NDC | 0078-0526 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Tasigna |
| Generic Name | Nilotinib |
| Dosage Form | Capsule |
| Route of Administration | ORAL |
| Marketing Start Date | 2007-10-29 |
| Marketing Category | NDA / NDA |
| Application Number | NDA022068 |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Substance Name | NILOTINIB |
| Active Ingredient Strength | 200 mg/1 |
| Pharm Classes | Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2007-10-29 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA022068 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2007-10-29 |
| Marketing Category | NDA |
| Application Number | NDA022068 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2007-10-29 |
| Ingredient | Strength |
|---|---|
| NILOTINIB | 200 mg/1 |
| SPL SET ID: | 6093952a-5248-45cb-ad17-33716a411146 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0078-0526 | Tasigna | nilotinib |
| 0078-0592 | Tasigna | nilotinib |
| 0078-0951 | Tasigna | nilotinib |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() TASIGNA 79062925 3635627 Live/Registered |
Novartis AG 2008-08-07 |
![]() TASIGNA 78458843 2995313 Dead/Cancelled |
Novartis AG 2004-07-29 |